Celgene has announced that it has received European Commission approval for its new blood cancer drug pomalidomide.
The regulatory body has ratified the compound for use in combination with dexamethasone for adult patients with relapsed and refractory multiple myeloma who have have demonstrated disease progression despite receiving at least two prior therapies, including both lenalidomide and bortezomib.
“Celgene has received European regulatory approval for pomalidomide, a new therapy for relapsed and refractory multiple myeloma.“
Data from the phase III trial MM-03 that demonstrated the drug's progression-free survival benefits formed the basis of the European Commission's decision.
Following this announcement, Celgene plans to launch the product in Europe under the trade name Imnovid.
Alan Colowick, president of Celgene in Europe, the Middle East and Africa, said: "With today's approval, Celgene becomes one of the few companies to deliver treatments across all stages of multiple myeloma, right from the start at diagnosis."
This comes after the firm announced positive trial data earlier this week that showed the benefits its drug Revlimid can offer in the treatment of smouldering multiple myeloma.See all the latest jobs in Pharmaceutical